Novagant, Inc. Launches E-Commerce Website at GLAVAPE.com for New Medical Cannabis Products

Novagant, Inc. Launches E-Commerce Website at GLAVAPE.com for New Medical Cannabis Products

DENVER, CO--(Marketwired - July 01, 2014) - Novagant, Inc. (PINKSHEETS: NVGT) is pleased to announce that it has launched its new E-Commerce portal website for its new GLAVAPE™ product at www.glavape.com. The company previously announced its new GLAVAPE™ Cannabidiol-rich hemp oil vape product to enter into a potential $8.4 billion medical cannabis industry. 

The new website is dedicated solely to the marketing and sale of GLAVAPE™ Vaporizer which is the most commercially available source of legal Cannabidiol without need for a medical cannabis prescription.

The www.glavape.com website allows for the purchase of the GLAVAPE™ product by PayPal. 

GLAVAPE™ is lab tested multiple times during the manufacturing process, from seed to shelf. The Company tests for CBD content, other cannabinoid content, yeast/mold/fungus, and bacteria like E. coli to ensure safety and quality. GLAVAPE™ 0.3ml Pen Tip is 100% natural and derived from the federally-legal industrial hemp plant. The unique hemp cultivars, combined with proprietary technologies, produce the highest quality CBD-rich hemp oil in the world.

The GLAVAPE™ product can be viewed: http://glavape.com/index.php?route=product/product&product_id=50

The GLAVAPE™ Pen is available in 0.3ml, 0.6ml, and 1.0ml and sizes. The MSRP is to debut at only $33 USD for the 0.3ml Pen Tip.

About Novagant, Inc. Novagant, Inc. was incorporated in the state of Nevada on February 23, 1987 under the name of Kendrex Systems, Inc. The Company underwent several name changes, and ultimately on November 26, 2013 changed its name to Novagant, Inc. For more information about the Company, please visit www.novagant.com.

Safe Harbor: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact: Novagant, Inc. [e-mail]